Top > Search of International Patents > CULTURE MEDIUM FOR PLURIPOTENT STEM CELLS

CULTURE MEDIUM FOR PLURIPOTENT STEM CELLS meetings

Foreign code F180009650
File No. 4447
Posted date Nov 21, 2018
Country WIPO
International application number 2015JP059104
International publication number WO 2015147047
Date of international filing Mar 25, 2015
Date of international publication Oct 1, 2015
Priority data
  • P2014-064174 (Mar 26, 2014) JP
Title CULTURE MEDIUM FOR PLURIPOTENT STEM CELLS meetings
Abstract The purpose of the present invention is to provide a medium which contains a protein component in a less amount and is capable of maintaining pluripotent stem cells in an undifferentiated state. A culture medium for pluripotent stem cells that contains (A) a GSK3β inhibitor and (B) a DYRK inhibitor.
Outline of related art and contending technology BACKGROUND ART
IPS cells or the pluripotent stem cells such as ES cells, its pluripotency and proliferative potential from, cell transplantation therapy, drug discovery or the like can not be utilized, and as research tools to disease has been expected. Typically, the pluripotent stem cells, serum and, in the presence of appropriate factors to the cells if, nearly indefinitely in an undifferentiated state while maintaining the self-replicate. For example, human pluripotent stem cell as the appropriate factors, such as bFGF and TGF β have been reported on the differentiation protein. However, these differentiation proteins, generally are very expensive and, in an undifferentiated state in order to maintain the required amount of being very much larger, the use of pluripotent stem cells are largely obstructed from the standpoint of cost.
In addition, when the device is applied to cell transplantation, pluripotent stem cells having uniform properties to the need, per lot and that the nature of the protein is likely to be different, as much as possible is desirable not to use the media components.
Under such circumstances, in recent years, as a protein bFGF, TGF β, insulin, and transferrin that contain only one species of the medium (E8 medium) 4 or (non-patent document 1 and 2, as well as Patent Document 1), as a protein Wnt, insulin, and transferrin that contain only one species of the medium 3 have been reported (non-patent document 3 and patent document 2).
However, the two media is 2, which are typically very expensive still bFGF, TGF β, since Wnt and the like, which can be prepared at lower cost has been desired in the medium. In addition, in the case of using the latter medium, if cell growth is relatively slow, in order to obtain a certain number of cells more medium is required.
Scope of claims (In Japanese)請求の範囲 [請求項1]
(A)GSK3β阻害剤、及び
(B)DYRK阻害剤
を含有する多能性幹細胞培養用培地。

[請求項2]
血清を含まない、請求項1に記載の培地。

[請求項3]
分化抑制タンパク質を含まない、請求項1又は2に記載の培地。

[請求項4]
含有されるタンパク質成分がインスリン及びトランスフェリンのみである、請求項1~3のいずれかに記載の培地。

[請求項5]
(A)成分が1-AzaKenpaullone、Kenpaullone、及びCHIR99021からなる群より選択される少なくとも1種である、請求項1~4のいずれかに記載の培地。

[請求項6]
(A)成分が1-AzaKenpaulloneである、請求項1~5のいずれかに記載の培地。

[請求項7]
(B)成分がID-8、Harmine、及びIndirubin類似体からなる群より選択される少なくとも1種である、請求項1~6のいずれかに記載の培地。

[請求項8]
(B)成分がID-8である、請求項1~7のいずれかに記載の培地。

[請求項9]
更に、(C)NFAT阻害剤を含有する、請求項1~8のいずれかに記載の培地。

[請求項10]
(C)成分がTacrolimusである、請求項9に記載の培地。

[請求項11]
フィーダー細胞非存在下での培養用である、請求項1~10のいずれかに記載の培地。

[請求項12]
多能性幹細胞が霊長類由来細胞である、請求項1~11のいずれかに記載の培地。

[請求項13]
請求項1~12のいずれかに記載の培地を用いる、多能性幹細胞の培養方法。

[請求項14]
(A)GSK3β阻害剤、及び
(B)DYRK阻害剤
を含有する、多能性幹細胞の分化抑制剤。

  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • KYOTO UNIVERSITY
  • Inventor
  • HASEGAWA, Kouichi
  • YASUDA, Shinya
  • SHAHSAVARANI, Hosein
  • YOSHIDA, Noriko
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by e-mail or facsimile if you have any interests on this patent. Thanks.

PAGE TOP

close
close
close
close
close
close